FABP5 and hepatocellular carcinoma: We propose that ICT exerts its multi-target anti-HCC activity through synergistic mechanisms—inhibiting CA9 (microenvironment regulation), UCK2 (nucleotide metabolism), and FABP5 (lipid metabolism), while enhancing CYP2C9 expression, which collectively contribute to its potent antitumor efficacy.